Inspire Medical Systems, Inc.
NYSE:INSPMedical - Devices
+$0.51 today
- Market cap
- $1.68B
- Beta
- 0.73
- P/E (TTM)
- 9.1
- EPS (TTM)
- $4.57
Volume 0.51M
Average 1.13M
INSP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Inspire Medical Systems, Inc.NYSE: INSP
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $24.7M fell 5.8% year over year, ahead of the -9.7% change in trailing-twelve-month research & development. Sequentially, it fell 4.4% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.
Context
- Research & development amounted to 11.3% of revenue in FY2025, down 2.9 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -5.8% holds above the trailing-twelve-month pace of -9.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 103.17M USD
- Year-over-year change
- -9.6%
- 4-year CAGR
- +28.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 103.17M | -9.6% |
| FY2024 | 2024-12-31 | 114.13M | -2.1% |
| FY2023 | 2023-12-31 | 116.54M | +69.8% |
| FY2022 | 2022-12-31 | 68.65M | +83.8% |
| FY2021 | 2021-12-31 | 37.35M | — |
Research & Development vs competitors
How INSP compares with its peers on the latest reported figures
- INSP's LTM Jun 2026 research & development of $99.68M is the 2nd highest of the 9 companies compared; the peer median is $23.6M.
- Its year-over-year change of -9.7% is the 5th highest of 6, against a peer median of +2.5%.
- Research & development amounts to 11.1% of revenue for INSP, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $497M | +2.5% | +22.0% | 424.8% | |
| LTM Jun 2026 | $99.68M | -9.7% | +14.5% | 11.1% | |
| LTM Mar 2026 | $73.13M | +11.5% | +35.0% | 22.7% | |
| LTM Jul 2026 | $48.58M | -4.7% | -8.1% | 2.6% | |
| LTM Mar 2026 | $33.1M | +17.2% | -7.3% | 7.2% | |
| LTM Mar 2026 | $14.1M | -9.9% | +2.1% | 5.5% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding INSP) | $23.6M | +2.5% | +2.1% | 4.1% | |
Competitors are the stored peer set for INSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 233.39M | 407.86M | 624.8M | 802.8M | 911.98M |
| Cost of Revenue | 33.28M | 66.12M | 96.58M | 122.99M | 133.23M |
| Gross Profit | 200.12M | 341.74M | 528.22M | 679.82M | 778.76M |
| Gross Margin | 85.7% | 83.8% | 84.5% | 84.7% | 85.4% |
| Research & Development | 37.35M | 68.65M | 116.54M | 114.13M | 103.17M |
| Selling, General & Admin | 202.62M | 320.69M | 451.96M | 529.61M | 624.64M |
| Operating Expenses | 239.97M | 389.33M | 568.49M | 643.74M | 727.8M |
| Depreciation & Amortization | 1.22M | 1.86M | 2.85M | 6.55M | 13.96M |
| EBITDA | (38.62M) | (40.73M) | (17.06M) | 65.03M | 79.79M |
| EBITDA Margin | -16.5% | -10.0% | -2.7% | 8.1% | 8.7% |
| Operating Income | (39.85M) | (47.59M) | (40.27M) | 36.08M | 50.95M |
| Operating Margin | -17.1% | -11.7% | -6.4% | 4.5% | 5.6% |
| Interest Income | 125K | 5.05M | 20.56M | 23.25M | 17.54M |
| Interest Expense | 2.13M | 1.68M | 0 | 22K | 137K |
| Other Income / Expenses | (2.12M) | 3.32M | 20.37M | 22.37M | 14.74M |
| Income Before Tax | (41.97M) | (44.27M) | (19.91M) | 58.45M | 65.7M |
| Pre-Tax Margin | -18.0% | -10.9% | -3.2% | 7.3% | 7.2% |
| Income Tax Expense | 72K | 613K | 1.25M | 4.94M | (79.73M) |
| Net Income | (42.04M) | (44.88M) | (21.15M) | 53.51M | 145.42M |
| Net Margin | -18.0% | -11.0% | -3.4% | 6.7% | 15.9% |
| EPS (Basic) | (1.54) | (1.60) | (0.72) | 1.80 | 4.95 |
| EPS (Diluted) | (1.54) | (1.60) | (0.72) | 1.75 | 4.89 |
| Weighted Avg Shares | 27.26M | 28.07M | 29.3M | 29.76M | 29.37M |
| Weighted Avg Shares (Diluted) | 27.26M | 28.07M | 29.3M | 30.54M | 29.76M |
Inspire Medical Systems, Inc.
NYSE:INSP
Intrinsic Alpha fair value
Locked
Current Price
$58.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.